There is a growing number of new therapies targeting different pathways that will revolutionize patient management strategies in castration-resistant prostate cancer (CRPC) patients. Today there are more clinical trial options for CRPC treatment than ever before. and there are many promising agents in late-stage clinical testing. The hypothesis that CRPC frequently remains driven by a... https://www.ngetikin.com/